| Geoffrey Anderson, MD | |
|
92 Beacon St, 1b, Boston, MA 02108-3325 | |
| (617) 763-6900 | |
| Not Available |
| Full Name | Geoffrey Anderson |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 18 Years |
| Location | 92 Beacon St, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144420951 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0127X | Surgery - Trauma Surgery | A100789 (California) | Primary |
| 208600000X | Surgery | 247890 (Massachusetts) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brigham And Women's Hospital | Boston, MA | Hospital |
| Sturdy Memorial Hospital | Attleboro, MA | Hospital |
| Faulkner Hospital-brigham And Women's | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brigham And Women's Physicians Organization Inc | 3870405988 | 2510 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013.
The Maryland Stem Cell Research Commission has completed its evaluation of the 141 applications in response to its three official Requests for Applications during the FY 2010 funding cycle. The board of directors of the Maryland Technology Development Corporation reviewed the Commission's recommendations and approved 42 projects totaling $11.7 million in funding through the Maryland Stem Cell Research Fund under the Maryland Stem Cell Research Act of 2006.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder.
› Verified 3 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013.
The Maryland Stem Cell Research Commission has completed its evaluation of the 141 applications in response to its three official Requests for Applications during the FY 2010 funding cycle. The board of directors of the Maryland Technology Development Corporation reviewed the Commission's recommendations and approved 42 projects totaling $11.7 million in funding through the Maryland Stem Cell Research Fund under the Maryland Stem Cell Research Act of 2006.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder.
› Verified 3 days ago
| Entity Name | The General Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013.
The Maryland Stem Cell Research Commission has completed its evaluation of the 141 applications in response to its three official Requests for Applications during the FY 2010 funding cycle. The board of directors of the Maryland Technology Development Corporation reviewed the Commission's recommendations and approved 42 projects totaling $11.7 million in funding through the Maryland Stem Cell Research Fund under the Maryland Stem Cell Research Act of 2006.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder.
› Verified 3 days ago
| Entity Name | Brigham And Women's Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033535497 PECOS PAC ID: 3870405988 Enrollment ID: O20150107001260 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013.
The Maryland Stem Cell Research Commission has completed its evaluation of the 141 applications in response to its three official Requests for Applications during the FY 2010 funding cycle. The board of directors of the Maryland Technology Development Corporation reviewed the Commission's recommendations and approved 42 projects totaling $11.7 million in funding through the Maryland Stem Cell Research Fund under the Maryland Stem Cell Research Act of 2006.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Geoffrey Anderson, MD 2051 Morengo St, Ipt, C5l100, Los Angeles, CA 90033 Ph: (617) 763-6900 | Geoffrey Anderson, MD 92 Beacon St, 1b, Boston, MA 02108-3325 Ph: (617) 763-6900 |
News Archive
Oramed Pharmaceuticals Inc., a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013.
The Maryland Stem Cell Research Commission has completed its evaluation of the 141 applications in response to its three official Requests for Applications during the FY 2010 funding cycle. The board of directors of the Maryland Technology Development Corporation reviewed the Commission's recommendations and approved 42 projects totaling $11.7 million in funding through the Maryland Stem Cell Research Fund under the Maryland Stem Cell Research Act of 2006.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder.
› Verified 3 days ago
Hugh G Auchincloss, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2000 | |
Nicole J Look-hong, MD, MSC Surgery Medicare: Medicare Enrolled Practice Location: Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 Phone: 617-724-3868 | |
Dr. Paul Jansson, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Neville House 236a, Boston, MA 02115 Phone: 617-732-5500 | |
Vanessa Mercedes Welten, MD MPH Surgery Medicare: Medicare Enrolled Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-732-5500 | |
Dr. Joanna Wolf Etra, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 110 Francis St Ste 9b, Boston, MA 02215 Phone: 617-632-9513 | |
Jennine Putnick, MD Surgery Medicare: Medicare Enrolled Practice Location: 330 Brookline Ave, Boston, MA 02215 Phone: 617-632-9511 | |
Michael Tarnoff, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 800 Washington St, Nemc Box 7105, Boston, MA 02111 Phone: 617-636-5000 |